KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $348.6 million.

  • Vertex Pharmaceuticals' Free Cash Flow fell 2914.63% to $348.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year increase of 50412.5%. This contributed to the annual value of $3.2 billion for FY2025, which is 50412.5% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Free Cash Flow stood at $348.6 million, which was down 2914.63% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Free Cash Flow registered a high of $1.3 billion during Q3 2024, and its lowest value of -$3.8 billion during Q2 2024.
  • In the last 5 years, Vertex Pharmaceuticals' Free Cash Flow had a median value of $897.0 million in 2022 and averaged $603.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 53529.65% in 2022, then tumbled by 45565.69% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Free Cash Flow (Quarter) stood at $933.2 million in 2021, then increased by 11.96% to $1.0 billion in 2022, then plummeted by 83.11% to $176.5 million in 2023, then surged by 178.75% to $492.0 million in 2024, then decreased by 29.15% to $348.6 million in 2025.
  • Its Free Cash Flow stands at $348.6 million for Q4 2025, versus $1.1 billion for Q3 2025 and $927.4 million for Q2 2025.